SECRETS To Capturing 200% Upsides On RETA: INTELLIGENCE FORECAST
As you can see, there is no shortage of information nowadays. After all, we're living in the digital information age.
While information can improve your knowledge, the quality of information is a "hit or miss." Simply put, there are many useless facts and garbage out there. Moreover, reading too much information can lead to information overload.
All of that is detrimental to your biotech investment gains. It prevents you from getting your Rolls Royce Phantom!
I know you're calling me full of shit. Here goes Dr. Tran, he's just never quit tooting his own horn.?
And right you are. After all, I run my own small business. There is no one else who is marketing for me. I have to do it myself. Would you do the same for your business?
If you did not shoot the messenger, I'll share with you my message to help you bank huge biotech profits. Allow me to illustrate my points through the story on Reata Pharmaceuticals (RETA).?
As you know, RETA had its PDUFA date set for March 28th. That's simply the date that the FDA would issue an approval decision for its lead drug, omaveloxolone ("Oma").
As a stellar medicine, Oma is designed to treat the deadly rare condition, Friedrich Ataxia: one without treatment alternatives.?
Before the 28th, most market news and Wall Street analysts were unanimously negative about Oma's approval prospects. They all said that there is no way the FDA would approve Oma.
Adding further insult to injury, news came out that Dr. Billy Dunn (former Head of the FDA Office of Neuroscience) that oversees Oma approval just retired. Given that Dr. Dunn is most inclined to approve Oma, his departure shocked RETA stock to the core.?
On the 27th, the market treated RETA as if the stock already receive a Complete Response Letter (i.e., CRL) or a non-approval.?Specifically, RETA shares tumbled over 30% in one single trading session.
If you focus on the news and information, you'd be overwhelmed and thereby thrown in the towel to sell out at a loss.
Instead, if you leverage?FORECASTING?like IBI members, you'd know that approval is forthcoming.
On the 27th, instead of running, IBI members doubled down on their holdings. Many started to place an outsized bet on RETA. Our members forecasted that Dr. Dunn already gave Oma the nod prior to his departure.
As someone who serves and assist our members, I forecasted Oma's approval with the "categorial 65%" (i.e., more than favorable) chances of approval. Given that my 65% category hits 86.2% all these years, that is the chance that members can expect to see Oma's approval.
As you can see, I'm the only one in the market who publicly forecasts and keeps track of my records. Not saying, "I told you so." But the record-keeping with specific accuracy percentage simply allows our IBI members to know what to expect from my forecasting.
Before dinner time on the 28th, the FDA issued a lifesaving decision for patients afflicted with FA in the form of approval! The stock then lit up in the green like a Christmas tree. It traded in the range of 150% to 180%.
The following day on March 1, IBI members celebrate and took profits on the RETA. In our usual IBI tradition, I did a role call to see how many shares members traded and if they had sold:
If you invest in biotech and you don't forecast (or belong to a community that forecast), it's like you're driving on the highway blindfolded. No matter how intelligent you are, not forecasting is like trying to paint without a brush. You won't get the results.
Now, if you miss all the big plays like AXSM, ITCI, NVCR, ITCI, TGTX, and RETA, there are more coming up this year. You know I don't bullshit you when I say there are more plays ...
You definitely don't want to miss out!
Asides from the binary event plays, I'm delighted to serve and assist our members. See what members are saying about IBI:
I shift through the world of biotech to always bring more plays for you daily.
Disclosure:?I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.
Additional disclosure:?As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, I'm not giving you professional medical advice. Before embarking on any health-changing behavior, make sure you consult with your own doctor.